Gsk (GSK) Receivables - Net (2016 - 2025)
Gsk (GSK) has 9 years of Receivables - Net data on record, last reported at $8.8 billion in Q4 2024.
- For Q4 2024, Receivables - Net fell 4.28% year-over-year to $8.8 billion; the TTM value through Dec 2024 reached $8.8 billion, down 4.28%, while the annual FY2024 figure was $8.7 billion, 4.87% down from the prior year.
- Receivables - Net reached $8.8 billion in Q4 2024 per GSK's latest filing, down from $9.2 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $10.6 billion in Q4 2021 and bottomed at $7.3 billion in Q4 2020.
- Average Receivables - Net over 5 years is $8.8 billion, with a median of $8.8 billion recorded in 2024.
- Peak YoY movement for Receivables - Net: surged 44.6% in 2021, then fell 21.92% in 2022.
- A 5-year view of Receivables - Net shows it stood at $7.3 billion in 2020, then soared by 44.6% to $10.6 billion in 2021, then dropped by 21.92% to $8.3 billion in 2022, then increased by 10.8% to $9.2 billion in 2023, then fell by 4.28% to $8.8 billion in 2024.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $8.8 billion in Q4 2024, $9.2 billion in Q4 2023, and $8.3 billion in Q4 2022.